Two stocks in Basic Materials
Grupa Kęty vs Novonesis A/S: profit, growth, debt and price compared
Grupa Kęty is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Novonesis A/S is stronger on 3: profit margin, debt and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Grupa KętyKTY.WA | Novonesis A/SNSIS-B.CO | |
|---|---|---|
| Net margin | 11.8% | Stronger: 15.6% |
| Revenue growth, past year | Stronger: +13.00% | +7.10% |
| Debt to equity | 57.0% | Stronger: 27.9% |
| Forward P/E | Stronger: 20.1× | 26.0× |
| Dividend yield | Stronger: 3.77% | 1.46% |
| Analysts | Hold · 6 | Stronger: Buy · 15 |
| From its 200-day average | Stronger: +9.7% | +6.9% |
Share price over the past year
- Grupa Kęty+38.6%
- Novonesis A/S+10.2%
17 Nov 202518 Nov 2026
Grupa Kęty or Novonesis A/S: which is stronger?
- NSIS-B.CO
Which is more profitable?
Novonesis A/S keeps more of each sale as profit: 15.6% against 11.8%.
- KTY.WA
Which is growing its sales faster?
Grupa Kęty is growing its sales faster: +13.00% over the past year, against +7.10%.
- NSIS-B.CO
Which has borrowed less?
Novonesis A/S has borrowed less: its debt is 27.9% of what its shareholders own, against 57.0% for Grupa Kęty.
- KTY.WA
Which costs less for the profit it is expected to make?
Grupa Kęty costs less for the profit it is expected to make: 20.1× its forward earnings, against 26.0×.
- KTY.WA
Which pays more in dividends?
Grupa Kęty pays more back in dividends for what a share costs: 3.77% a year, against 1.46%.
- NSIS-B.CO
Which do analysts rate higher?
Analysts are warmer on Novonesis A/S: Buy, against Hold for Grupa Kęty.
- KTY.WA
Which is in the stronger price trend?
Grupa Kęty's price is in the stronger trend: 9.7% above its 200-day average, against 6.9% above.
What each company does
KTY.WAGrupa Kęty
Grupa Kęty S.A. produces and sells aluminum profiles and components in Poland and internationally.
Reports results on 25 March 2027
NSIS-B.CONovonesis A/S
Novonesis A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America.
Reports results on 24 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.